Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The SYDNEY Device Study
NCT03415178Phase 3Completed
- Sponsor
- Sanofi
- Start
- Mar 2018
- Primary completion
- Aug 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of alirocumab in hypercholesterolemia, sponsored by Sanofi. Started Mar 2018; status: completed.
02
Drugs
alirocumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT03415178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03415178.